Akili is a Boston-based digital medicine company that develops software-based therapeutic products to treat cognitive dysfunction. Its pipeline targets conditions including ADHD, multiple sclerosis, and depression. The company is focused on digital-medicine interventions rather than traditional pharmaceuticals. Financially, Akili completed a $55M Series C funding round announced in May 2018. The Series C was led by Temasek and included participation from Baillie Gifford, Amgen Ventures, M Ventures, JAZZ Venture Partners, Canepa Advanced Healthcare Fund, and Brooklands Capital Strategies. The financing reflects institutional investor support for the company’s ongoing development efforts. Akili is a digital medicine company developing clinically validated, non-pharmacological therapeutics and diagnostics for cognitive disorders delivered in an action video game interface. Its lead product platform, Project: EVO, licensed from Dr. Adam Gazzaley's lab at UCSF, targets the neurological ability to process multiple streams of information and adapts difficulty in real time. The intervention aims to improve attention, working memory, and other executive functions, while the monitoring product may enable screening and disease tracking across neurological and psychiatric disorders. Akili is conducting multiple clinical trials, including a pivotal STARS-ADHD trial of Project: EVO in pediatric ADHD, and studies in autism, depression, Alzheimer's disease, traumatic brain injury, Parkinson's disease, and multiple sclerosis. The company plans to expand clinical development into neurodegeneration and to build out commercial infrastructure as it nears market with late-stage products. Financially, Akili announced an $11.9 million expansion of its recent Series B, bringing total Series B proceeds to $42.4 million, with new investments from M Ventures and Amgen Ventures and prior backers including Pfizer and Shire.

Total raised

$67M

Funding rounds

2

Latest round

Series C

Latest activity

May 2018